HDAC
Histone deacetylases (HDACs), known for their ability to target histones as well as more than 50 non-histone proteins, are classified into three major classes according to their homology to yeast proteins, including class I (HDAC1, HDAC2, HDAC3 and HDAC8), class II (HDAC4, HDAC5, HDAC7 and HDAC9) and class IV (HDAC11). HDAC inhibitors, a large group of compounds that is able to induce the accumulation of acetylated histones as well as non-histone proteins, are divided into several structural classes including hydroxamates, cyclic peptides, aliphatic acids and benzamides. HDAC inhibitors have been investigated for their efficacy as anticancer agents in the treatment of a wild range of cancers.
-
B5949 BG45Summary: Novel HDAC3-selective inhibitor
-
B5967 UF 010Summary: Novel and selective class I HDAC inhibitor
-
B5968 BML-210(CAY10433)Summary: Novel HDAC inhibitor
-
B5969 2-hexyl-4-Pentynoic AcidSummary: Potent and robust HDACs inhibitor
-
C4018 4-iodo-SAHASummary: class I and class II histone deacetylase (HDAC) inhibitor
-
B4890 HPOB1 CitationTarget: Histone Deacetylases (HDACs)Summary: HDAC6 inhibitor, potent and selective
-
B3704 Nexturastat ATarget: Histone Deacetylases (HDACs)Summary: HDAC6 inhibitor,highly potent and selective
-
B4106 4SC-202Summary: Class I HDAC inhibitor
-
B4655 BMS-345541(free base)Summary: IKK-1/IKK-2 inhibitor,potent and selective
-
C5334 BRD6688Summary: HDAC inhibitor